BRPI0409405A - compostos 7-aza-quinazolina substituìdos - Google Patents

compostos 7-aza-quinazolina substituìdos

Info

Publication number
BRPI0409405A
BRPI0409405A BRPI0409405-0A BRPI0409405A BRPI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A BR PI0409405 A BRPI0409405 A BR PI0409405A
Authority
BR
Brazil
Prior art keywords
aza
substituted
quinazoline compounds
compounds
quinazoline
Prior art date
Application number
BRPI0409405-0A
Other languages
English (en)
Inventor
Nolan James Dewdney
David Michael Goldstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409405A publication Critical patent/BRPI0409405A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS 7-AZA-QUINAZOLINA SUBSTITUìDOS". A presente invenção refere-se a compostos de Fórmula (I) ou (II) onde R, R6, R7 e Q são como indicados no relatório descritivo. Os compostos são de utilidade como inibidores de p38 quinase, podendo ser usados no tratamento de distúrbio mediado por p38.
BRPI0409405-0A 2003-04-16 2004-04-13 compostos 7-aza-quinazolina substituìdos BRPI0409405A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46322903P 2003-04-16 2003-04-16
PCT/EP2004/003883 WO2004091625A1 (en) 2003-04-16 2004-04-13 (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis

Publications (1)

Publication Number Publication Date
BRPI0409405A true BRPI0409405A (pt) 2006-04-25

Family

ID=33300055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409405-0A BRPI0409405A (pt) 2003-04-16 2004-04-13 compostos 7-aza-quinazolina substituìdos

Country Status (16)

Country Link
US (2) US7189731B2 (pt)
EP (1) EP1620105B1 (pt)
JP (1) JP2006523640A (pt)
KR (1) KR20060006037A (pt)
CN (1) CN1774250A (pt)
AR (1) AR044515A1 (pt)
AU (1) AU2004229163A1 (pt)
BR (1) BRPI0409405A (pt)
CA (1) CA2520785A1 (pt)
CL (1) CL2004000805A1 (pt)
DE (1) DE602004004259T2 (pt)
ES (1) ES2279361T3 (pt)
MX (1) MXPA05010975A (pt)
RU (1) RU2005135329A (pt)
TW (1) TW200503722A (pt)
WO (1) WO2004091625A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
RU2293560C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ лечения хронических гонартритов у больных остеоартрозом
RU2293559C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ подготовки к любрикантной терапии
ES2303758B1 (es) * 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
RU2011141121A (ru) 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
JPS4936700A (pt) * 1972-08-16 1974-04-05
US4672116A (en) 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
US5084463A (en) 1989-12-11 1992-01-28 American Home Products Corporation N-quinolinyl alkyl-substituted 1-aryloxy-2-propanolamine and propylamine derivatives possessing class III antiarrhythmic activity
US20020061879A1 (en) 1996-02-02 2002-05-23 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP1014953B1 (en) 1997-03-05 2012-04-25 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
US6313294B1 (en) 1998-02-04 2001-11-06 Development Center For Biotechnology Process for preparing amides
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
EP1110552A1 (en) 1999-12-22 2001-06-27 Aventis Pharma S.A. Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy
AU2001245401A1 (en) 2000-03-01 2001-09-12 Sumitomo Pharmaceuticals Company, Limited Hydrazones and analogs as cholesterol lowering agents
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
SK11322003A3 (en) * 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
RU2324695C2 (ru) * 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38

Also Published As

Publication number Publication date
US20040209903A1 (en) 2004-10-21
WO2004091625A1 (en) 2004-10-28
KR20060006037A (ko) 2006-01-18
AU2004229163A1 (en) 2004-10-28
AR044515A1 (es) 2005-09-14
JP2006523640A (ja) 2006-10-19
CA2520785A1 (en) 2004-10-28
DE602004004259D1 (de) 2007-02-22
EP1620105A1 (en) 2006-02-01
ES2279361T3 (es) 2007-08-16
CL2004000805A1 (es) 2005-02-04
RU2005135329A (ru) 2006-08-10
US7189731B2 (en) 2007-03-13
US20070135459A1 (en) 2007-06-14
TW200503722A (en) 2005-02-01
EP1620105B1 (en) 2007-01-10
MXPA05010975A (es) 2005-11-28
DE602004004259T2 (de) 2007-11-15
CN1774250A (zh) 2006-05-17

Similar Documents

Publication Publication Date Title
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE517896T1 (de) P38-kinase-inhibitoren
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
BR0112965A (pt) Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inibidores de glocogênio sintase cinase-3beta
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
CY1112947T1 (el) Παραγωγα πυρρολης καταλληλα για την θεραπεια πολλαπλασιαστικων ασθενειων
BRPI0409580A (pt) compostos de quinazolina
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
BR0313634A (pt) Derivados de benzimidazol
ATE429228T1 (de) Derivate von piperazine-2-carboxamide
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE452896T1 (de) C3-cyanoepothilonderivate
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
BRPI0407913A (pt) antagonistas receptores de ccr-3
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
TW200503722A (en) Substituted 7-aza-quinazoline compounds
TW200740816A (en) P38 MAP kinase inhibitors and methods for using the same

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired